The website will be down at times for maintenance from 8:00 a.m. CT Saturday, March 2 through 10:00 a.m. CT Sunday, March 3.

brand logo

Am Fam Physician. 2013;87(5):310

Error in table column headings. In the editorial “Latent Autoimmune Diabetes in Adults” (April 1, 2010, p. 843), Table 1 (p. 844) contained errors in the column headings. The rightsholder of the original table, which contained these errors, granted AFP permission to reprint the table as published. The heading over the fourth column (Diabetes) should have been “Type 1 diabetes” and appeared over the third column. The heading over the third column (Latent autoimmune type 1 diabetes) should have been “Latent autoimmune diabetes in adults” and appeared over the fourth column. The table has been corrected online and is reprinted here.

FeaturesType 2 diabetesType 1 diabetesLatent autoimmune diabetes in adults
KetoacidosisUsually absentWill develop rapidly unless patient receives insulin replacement therapyAbsent at diagnosis, but may be present when patient becomes severely insulinopenic
Cardiovascular complicationsRisk 2–4 times higher than individuals who are euglycemicIncreased risk of cardiovascular morbidity and mortality related to strokes, acute coronary events, and coronary revascularizations; high incidence rates compared with euglycemic individuals, especially in womenSame risk as patients with T2DM
Microvascular complications (retinopathy, nephropathy, neuropathy)IncreasedIncreasedIncreased
PathophysiologyPeripheral insulin resistance; reduced pancreatic beta-cell mass and function; reduced insulin secretionAutoimmune destruction of pancreatic beta-cellsLatent autoimmune destruction of pancreatic beta-cells
AutoantibodiesNegative
  • GAD-65 autoantibodies

  • Islet-cell antigen-2

  • Insulin autoantibodies

  • note: Unlike LADA, T1DM patients typically are positive for all three autoantibodies

  • GAD-65 autoantibody is typically the only one detected

  • Islet-cell antibodies

Insulin requirements for treatmentUsually late in the disease when the remaining beta-cell mass and function can no longer support acceptable glycemic control achieved by oral agents or incretin mimeticsInsulin is required from the time of diagnosisInsulin should be initiated as soon as the patient develops autoantibodies

Continue Reading


More in AFP

Copyright © 2013 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.